RESUMO
Thirty patients with advanced carcinoma of the prostate were treated with estramustine phosphate. All patients were followed up for a minimum of 9 months. Of 15 not previously treated with oestrogens 9 responded objectively and 11 subjectively. Of 15 patients whose tumours had failed to respond to at least 2 oestrogens, 3 responded objectively and 5 subjectively. Adverse effects consisted of cardiovascular complications, gynaecomastia and impotence. Gastrointestinal side effects were minimal and no hepatic, renal or marrow toxicity was seen. The criteria of assessment of response are discussed.
Assuntos
Estramustina/uso terapêutico , Compostos de Mostarda Nitrogenada/uso terapêutico , Neoplasias da Próstata/tratamento farmacológico , Estramustina/efeitos adversos , Estrogênios/uso terapêutico , Humanos , Masculino , Fatores de TempoRESUMO
The efficacy of an association of cyclophosphamide (CPM) and 5-fluorouracil was studied in 15 patients with prostate cancer not responding to oestrogen therapy, and more particularly its effect on pain due to bone metastases. No objective improvement was noted with this association, but there was a definitite reduction in bone metastases pain in 5 of the patients, with an average remission time of 4 months. Half of the patients had nausea and vomiting, but in spite of this digestive intolerance those patients who obtained pain relief for 4 months considered the treatment to be of positive value. This therapy is recommended only fater the failure of castration, anti-androgens, and oestrogens, together with nitrogen mustard (Estracyt) and corticotherapy.
Assuntos
Neoplasias Ósseas/secundário , Ciclofosfamida/uso terapêutico , Fluoruracila/uso terapêutico , Neoplasias da Próstata/tratamento farmacológico , Neoplasias Ósseas/tratamento farmacológico , Ensaios Clínicos como Assunto , Resistência a Medicamentos , Quimioterapia Combinada , Estrogênios/uso terapêutico , Humanos , Masculino , Cuidados PaliativosRESUMO
Seven patients with advanced testicular tumors, resistant to existing chemotheurapeutic agents, were treated with a new antitumor agent, the Cisplatinum (associated to mannitol induced hyperdiuresis). There were 3 objective remissions (1 complete and 2 partial). Major toxicity was gastrointestinal. There was little renal and hematologic toxicity in our serie. The drug may have use in combination therapy in advanced non seminomatous testicular tumors.